Attenuation of Antiresorptive Action in Withdrawal of Minodronic Acid for Three Months After Treatment for Twelve Months in Ovariectomized Rats
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605520712 | ||
| 003 | CHVBK | ||
| 005 | 20210128100736.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-0017-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-0017-2 | ||
| 245 | 0 | 0 | |a Attenuation of Antiresorptive Action in Withdrawal of Minodronic Acid for Three Months After Treatment for Twelve Months in Ovariectomized Rats |h [Elektronische Daten] |c [Makoto Tanaka, Hiroshi Mori, Kazuhito Kawabata] |
| 520 | 3 | |a The purpose of this study was to evaluate the effects of withdrawal of minodronic acid (MIN) for 3months after 12months of treatment in ovariectomized (OVX) rat. OVX rats were orally treated with MIN (6, 30, and 150µg/kg/day) for 12months and necropsied on the day after the last dosing or following 3months of withdrawal. Lumbar and femoral BMD were decreased in OVX controls. MIN dose-dependently increased BMD. Withdrawal eliminated the effect of MIN on BMD loss after treatment at 6µg/kg, but not after treatment at 30 and 150µg/kg. In MIN-treated rats, trabecular thinning occurred during withdrawal after treatment at 6µg/kg, but the trabecular microstructure was maintained at 30 and 150µg/kg. In a mechanical test of the femoral diaphysis, stiffness of in OVX controls was decreased but ultimate load was similar to that in sham after withdrawal. MIN increased ultimate load and stiffness, but endosteal length decreased after withdrawal. Suppression of bone turnover by MIN based on bone turnover markers and histomorphometric indices was attenuated by withdrawal after treatment at 6 and 30µg/kg and partially at 150µg/kg. The MIN concentration in the humerus decreased during withdrawal, and half-life at 30µg/kg was shorter than that at 150µg/kg. These results show that the antiresorptive action of MIN was dose-dependently attenuated by 3-month withdrawal in a rat OVX model. An absence of BMD increase was only observed at a low dose but decreases in antiresorptive activity occurred over a wide dose range. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Minodronic acid |2 nationallicence | |
| 690 | 7 | |a Osteoporosis |2 nationallicence | |
| 690 | 7 | |a Bisphosphonate |2 nationallicence | |
| 690 | 7 | |a Withdrawal |2 nationallicence | |
| 690 | 7 | |a Ovariectomized rats |2 nationallicence | |
| 700 | 1 | |a Tanaka |D Makoto |u Research Promotion, Ono Pharmaceutical Co., Ltd., 3-1-1, Sakurai, Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | |
| 700 | 1 | |a Mori |D Hiroshi |u Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | |
| 700 | 1 | |a Kawabata |D Kazuhito |u Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/4(2015-10-01), 402-411 |x 0171-967X |q 97:4<402 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-0017-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-0017-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tanaka |D Makoto |u Research Promotion, Ono Pharmaceutical Co., Ltd., 3-1-1, Sakurai, Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mori |D Hiroshi |u Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kawabata |D Kazuhito |u Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Shimamoto-cho, 618-8585, Osaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/4(2015-10-01), 402-411 |x 0171-967X |q 97:4<402 |1 2015 |2 97 |o 223 | ||